Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06811233 · ClinicalTrials.gov registry record · Phase 2
Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
A Phase 2 study of Acute Myeloid Leukemia (AML), sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT06811233 is a Phase 2 study of Acute Myeloid Leukemia (AML) that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 140 participants, roughly in line with the 141-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT06811233, a Phase 2 study of Acute Myeloid Leukemia (AML), is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if metal detoxification (with calcium disodium edetate \[Ca-EDTA\] and dimercaptosuccinic acid \[DMSA\]) during standard therapy can help improve outcomes in patients with intermediate-risk, high-risk, or secondary AML compared to standard therapy alone. Researchers think lowering the level of metals found in the blood/bone marrow may help to control the disease and/or improve the response to chemotherapy.
Conditions Studied
Interventions
- DRUG Magnesium Sulfate
- DRUG DMSA
- DRUG Ca-EDTA
- DRUG Multivitamin
Study Locations (1)
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2025-05-08 |
| Est. Completion | 2031-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06811233
The ClinicalTrials.gov registry entry for NCT06811233 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 141-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Myeloid Leukemia (AML) appearing as the primary indexed condition, and to 4 interventions - of which Magnesium Sulfate is the first listed.
NCT06811233 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06811233 about?
NCT06811233 is a clinical study titled "Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study". The goal of this clinical research study is to learn if metal detoxification (with calcium disodium edetate \[Ca-EDTA\] and dimercaptosuccinic acid \[DMSA\]) during standard therapy can help improve outcomes in patients with intermediate-risk, high-risk, or secondary AML compared to standard therapy...
What is the current status of trial NCT06811233?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2025-05-08. Estimated completion is 2031-08-31.
What conditions does trial NCT06811233 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia (AML).
What interventions are being tested in trial NCT06811233?
The interventions under investigation include: Magnesium Sulfate (DRUG), DMSA (DRUG), Ca-EDTA (DRUG), Multivitamin (DRUG).
Who is sponsoring clinical trial NCT06811233?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06811233 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia (AML)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ivosidenib as Post-HSCT Maintenance for AML
RECRUITING · Phase 2
-
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
RECRUITING · Phase 2
-
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 2
-
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.